Deoxyribozyme‐based DNA Machines for Cancer Therapy

Authors: Nedorezova D.D.Fakhardo A.F., Molden T., Kolpashchikov D. M.


Soon after their discovery, RNA-cleaving deoxyribozymes (RCDZ) were explored as anti-cancer gene therapy agents. Despite low toxicity found in clinical trials, there is no clinically significant anti-cancer RCDZ - based therapy. Some of the reported disadvantages of RCDZ agents include poor accessibility to folded nucleic acids, low catalytic efficiency inside cells and problems of intracellular delivery. On the other hand, structural DNA nanotechnology provides opportunity to build multifunctional nano-associations that can address some of the problems. This Concept article discusses the possibility of building RCDZ-based multifunctional DNA nanomachines equipped with RNA unwinding, cancer marker recognition and RNA cleavage functions. An important advantage of such 'nanomachines' is the possibility to cleave a housekeeping gene mRNA in cancer cell-specific manner. The proposed design can become a starting point for building up sophisticated DNA-based nanodevices for cancer treatment.

DOI: 10.1002/cbic.201900525

Read Full Here: